The Onset of Action and the Analgesic Efficacy of Saridon®* (a Propyphenazone/Paracetamol/Caffeine Combination) in Comparison with Paracetamol, Ibuprofen, Aspirin and Placebo (Pooled Statistical Analysis)

Abstract

The objective was to evaluate the onset of action, analgesic efficacy and tolerability of Saridon*, a propyphenazone 150 mg/paracetamol 250 mg/caffeine 50 mg combination, in comparison with paracetamol 500 mg, aspirin 500 mg, ibuprofen 200 mg and placebo, by a pooled statistical analysis of eight studies. Out of 500 generally healthy patients (55.2% men, 44.8% women), average age 43.5 years, 329 (65.8%) had moderate and 171 (34.2%) severe acute dentoalveolar pain. More Saridon-treated patients reported 'pain gone/partly gone' and less 'pain unchanged or worse' compared with paracetamol, aspirin and placebo 30min (p = 0.009, p < 0.001, p = 0.001, respectively) and 60 min after dosing (p < 0.0001 for all). The difference with ibuprofen was observed 60 min after dosing (p < 0.01). Pain intensity differences 30 min and 60 min after dosing infer that Saridon has a faster onset of action than all of the other medications that it was compared with (ibuprofen at only 60 min after dosing). Total pain relief scores four hours after dosing were higher in the Saridon group compared with the paracetamol, ibuprofen, placebo (p < 0.0001 for all) and aspirin groups (p < 0.01). At the end of the study, patients assessed Saridon as more efficacious than the other study medications (p < 0.0001 for all). No serious adverse events were observed with any of the drugs studied. All medications were well tolerated. Twenty patients (4.0%) reported adverse events with no significant differences between groups. The most common adverse events were gastrointestinal disorders, followed by nervous system, skin, subcutaneous tissue, respiratory, cardiac and general disorders. Saridon is an effective analgesic that combines the advantage of fast onset and effective analgesia as compared with paracetamol alone, ibuprofen, aspirin or placebo. The results of this pooled analysis of eight studies should be confirmed in a double-blind study, since seven of the studies included in this analysis were single blind.

Comparison of pre-emptive ibuprofen, paracetamol, and placebo administration in reducing post-operative pain in primary tooth extraction

“…This procedure also allows post‐operative pain management using local anaesthetics, NSAIDs, and opioids, as reported in previously published dental studies 5 . Ibuprofen, a propionic acid derivative analgesic that provides anti‐inflammatory action, has been used in adult studies to evaluate its preoperative effect on post‐extraction pain relief following dental procedures 6,12–15 . It was found to be a safe and effective analgesic as an anti‐inflammatory agent in dosages ranging from 10 mg/kg/day to a maximum of 40 mg/kg/day 9 .…”

“…It was found to be a safe and effective analgesic as an anti‐inflammatory agent in dosages ranging from 10 mg/kg/day to a maximum of 40 mg/kg/day 9 . It reached the peak plasma concentration 30 min after administration 12–15 . Paracetamol is also a traditional antipyretic and analgesic drug, as characterized in textbooks.…”

Safety and tolerability of antipsychotics: focus on amisulpride

“…Thus, dopaminergic overactivity in the frontal cortex and underactivity in the limbic areas, can be treated simultaneously, alleviating both positive and negative symptoms of schizophrenia, respectively 46. Additionally, the finding that amisulpride is a highly effective antidepressant via antagonism at 5-HT 7 receptors would make its mechanism of action a unique one relative to other approved antidepressant drugs, and supports the development and/or testing of more selective 5-HT 7 receptor antagonists to treat depression in humans,16 including their effects on negative symptoms, cognitive dysfunction, mood, morbidity and mortality, work and social function, quality of life, and family and societal burden.…”

The Inflammatory Response After Ischemic Stroke: Targeting β2 and β1 Integrins

“…Langhauser et al went one step further and found that no treatment paradigm (prophylactic or therapeutic) and no model (transient or permanent) showed efficacy (Langhauser et al, 2014). On the other hand, both Becker, 2002 and Relton et al, 2000 found that inhibition of α 4 improved both infarct volumes and functional deficits. When a preclinical randomized control trial was implemented at multiple centers, researchers found efficacy only in patients with small infarct volumes (Llovera et al, 2015).…”

“…Though this mechanism is less obvious in the highly mobile leukocytes. Once leukocytes are bound to selectins, additional binding to integrins and adhesion molecules (intracellular adhesion molecule (ICAMs and vascular adhesion molecule-1 (VCAM) occurs, permitting leukocytic rolling (del Pozo et al, 1995; Lorant et al, 1995; Kindzelskii et al, 1996; Becker, 2002). Additional damage can occur once at the site of ischemia, as infiltration into the brain parenchyma across the BBB destroys surrounding vasculature (Clark et al, 1993; Chou et al, 2004), and leukocytes continually release additional factors (reactive oxygen species, cytokines, and proteases) that enhance leukocytic recruitment (Wang et al, 2008).…”